Twitxy Saved

Jason A. Mouabbi MD

Verified account This account is verified. Learn more

@JAMouabbi

Breast Medical Oncologist @mdandersonnews | Lobular Specialist | Lead of #ILC Working Group | co-Lead of HR+ Working Group | Chair of @LobularBCA
Houston, TX faculty.mdanderson.org/profiles/jason… Joined April 2009
888 Following 3.5K Followers 2.2K Posts

Latest posts 5

Jason A. Mouabbi MD Verified account @JAMouabbi
🧠 CNS activity of a TROP2 ADC in a randomized phase 3. #ESMO26 LBA96: brain mets analysis of TROPION-Breast02, Dato-DXd vs chemo in 1L TNBC patients who are not IO candidates. 🧵 #bcsm

61 of 644 patients had asymptomatic, stable brain mets (30 untreated, 31 previously treated). 24 had measurable intracranial disease.

🙌🏻 Intracranial response:
ORR 62.5% vs 37.5%, including a complete response
12-week intracranial disease control 75% vs 50%

🙌🏻 CNS PFS 9.5 vs 2.6 mo, HR 0.27 (95% CI 0.13–0.56). Systemic PFS in the brain mets group: 7.7 vs 3.5 mo, HR 0.37.

The signal held in *untreated* brain mets: PFS HR 0.29, OS HR 0.35. That's the group where systemic options matter most.

Bottom line: Dato-DXd is a reasonable systemic choice for 1L TNBC with brain mets.
0 replies 9 reposts 21 likes 992 views View on X
Jason A. Mouabbi MD Verified account @JAMouabbi
Excited to share our #ESMO26 poster 4260P 🧬

We asked: can reflex liquid NGS add to tissue NGS and tumor-informed ctDNA monitoring? 🧵 #bcsm #ctDNA

50 patients, 10 tumor types (34% breast), 101 plasma samples. Tissue NGS (Altera) + serial ctDNA (Signatera) + reflex liquid NGS.

Concordance 🙌🏻: every patient with a tissue-actionable alteration (26/26) had it found in plasma too.

Plasma added value 🙌🏻: new relevant or actionable alterations in ~20% of patients. Mostly acquired resistance: 👉🏻ESR1 after AI (switched to a SERD)
👉🏻BRCA2 reversions after PARPi
👉🏻Plus a plasma-only BRAF K601E that guided encorafenib.

Tracking: across 45 measurable plasma pairs, the two assays moved in the same direction 96% of the time (ρ = 0.76).

But they're NOT interchangeable. In an esophageal case on T-DXd, tumor-informed ctDNA showed a >1-log drop and a sharp rebound, while liquid NGS allele fraction barely moved.

🚨🚨Takeaway: tumor-informed ctDNA tells you *when* to look, and liquid NGS tells you *what* changed. Together they can guide real-time treatment decisions.

Grateful to my coauthors @NateraGenetics

Come by poster 4260P!